Barco's cardiac analysis suite gets FDA OK

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Barco has received FDA 510(k) pre-market clearance for its suite of clinical applications for structural and functional analysis of contrast-enhanced cardiac studies CARDIAMETRIX. CARDIAMETRIX is an option with Barco’s core software suite VOXAR 3D for advanced visualization and analysis.

CARDIAMETRIX is available for integration into PACS with VOXAR 3D and VESSELMETRIX, Barco’s optional clinical application for quantitative vessel analysis of CTA and MRA.

The VOXAR 3D CARDIAMETRIX suite features integrated clinical applications for coronary artery vessel analysis, calcium scoring, 4D cardiac analysis and left ventricular functional analysis. VOXAR 3D CARDIAMETRIX rapidly evaluates multi-phase studies using up to 6 phases to deliver high-quality visualization of 2D, 3D and 4D images of the heart. It provides an intuitive, productive and clinically effective reading methodology for efficient reading and reporting of cardiac work-ups, Barco said.

VOXAR 3D CARDIAMETRIX is also available as an optional clinical application with VOXAR 3D ENTERPRISE.